AU2022323827A1 - Anandamide cyclodextrin inclusion complex vehicles - Google Patents

Anandamide cyclodextrin inclusion complex vehicles Download PDF

Info

Publication number
AU2022323827A1
AU2022323827A1 AU2022323827A AU2022323827A AU2022323827A1 AU 2022323827 A1 AU2022323827 A1 AU 2022323827A1 AU 2022323827 A AU2022323827 A AU 2022323827A AU 2022323827 A AU2022323827 A AU 2022323827A AU 2022323827 A1 AU2022323827 A1 AU 2022323827A1
Authority
AU
Australia
Prior art keywords
cyclodextrin
citrulline
inclusion complex
anandamide
complex formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022323827A
Other languages
English (en)
Inventor
Al Czap
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Czap Research and Development LLC
Original Assignee
Czap Research and Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Czap Research and Development LLC filed Critical Czap Research and Development LLC
Publication of AU2022323827A1 publication Critical patent/AU2022323827A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01011—Dextranase (3.2.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022323827A 2021-08-04 2022-07-15 Anandamide cyclodextrin inclusion complex vehicles Pending AU2022323827A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163229447P 2021-08-04 2021-08-04
US63/229,447 2021-08-04
PCT/IB2022/056550 WO2023012552A1 (en) 2021-08-04 2022-07-15 Anandamide cyclodextrin inclusion complex vehicles

Publications (1)

Publication Number Publication Date
AU2022323827A1 true AU2022323827A1 (en) 2024-02-15

Family

ID=85155427

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022323827A Pending AU2022323827A1 (en) 2021-08-04 2022-07-15 Anandamide cyclodextrin inclusion complex vehicles

Country Status (9)

Country Link
US (1) US20250205181A1 (cg-RX-API-DMAC7.html)
EP (1) EP4380556A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024528990A (cg-RX-API-DMAC7.html)
KR (1) KR20240050356A (cg-RX-API-DMAC7.html)
CN (1) CN118043040A (cg-RX-API-DMAC7.html)
AU (1) AU2022323827A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227102A1 (cg-RX-API-DMAC7.html)
IL (1) IL310613A (cg-RX-API-DMAC7.html)
WO (1) WO2023012552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024199007A1 (zh) * 2023-03-28 2024-10-03 南京纽邦生物科技有限公司 花生四烯酸乙醇胺组合物
WO2025229618A1 (en) * 2024-05-02 2025-11-06 Czap Research And Development, Llc Blood glucose control with enzymatic cyclodextrin inclusion complex formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001558A1 (en) * 1994-07-11 1996-01-25 Pate David W Anandamide analogue compositions and method of treating intraocular hypertention using same
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20170224841A1 (en) * 2016-02-04 2017-08-10 Czap Reseach And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles
CN115154619B (zh) * 2016-02-04 2025-11-28 西泽普研究与发展有限责任公司 受控释放和层状的环糊精包合物媒介物
EP4653002A3 (en) * 2020-03-23 2026-02-25 Czap Research And Development, LLC Oral terpene cyclodextrin inclusion complex vehicles

Also Published As

Publication number Publication date
US20250205181A1 (en) 2025-06-26
WO2023012552A1 (en) 2023-02-09
EP4380556A1 (en) 2024-06-12
CA3227102A1 (en) 2023-02-09
KR20240050356A (ko) 2024-04-18
JP2024528990A (ja) 2024-08-01
CN118043040A (zh) 2024-05-14
EP4380556A4 (en) 2025-07-02
IL310613A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
US20200347153A1 (en) Methods for forming inclusion complexes with hydrophilic beta-cyclodextrin derivatives and compositions thereof
EP3892303A1 (en) Controlled-release and stratified cyclodextrin inclusion complex vehicles
EP4125830B1 (en) Oral terpene cyclodextrin inclusion complex vehicles
CN101534794A (zh) 用于递送眼科用药物的凝胶
JP5021305B2 (ja) 水溶性ジテルペンの調製方法およびその適用
WO2023012552A1 (en) Anandamide cyclodextrin inclusion complex vehicles
EP4309642A1 (en) Liquid preparation of l-serine or pharmaceutically acceptable salt thereof and method for preparing same
US20170224841A1 (en) Controlled-release and stratified cyclodextrin inclusion complex vehicles
CN117430541B (zh) 用于向细胞递送的化合物及其组合物
JP7623953B2 (ja) 医薬品または化粧品用組成物
JP4467978B2 (ja) ２−ヒドロキシプロピル−β−シクロデキストリンによるタキソールの包接錯体
US20170224842A1 (en) Controlled-release and stratified cyclodextrin inclusion complex vehicles
CN102362855B (zh) 一种伊曲康唑异构体口服溶液
WO2025229618A1 (en) Blood glucose control with enzymatic cyclodextrin inclusion complex formulations
CN102552140B (zh) 罗格列酮的液体组合物
WO2025229633A2 (en) Arterial plaque control with enzymatic cyclodextrin inclusion complex formulations
WO2025238557A1 (en) Cholesterol control with enzymatic cyclodextrin inclusion complex formulations
US20250009698A1 (en) Nervonic acid-based compositions and methods
CN120981219A (zh) 包含咪达唑仑的单位剂量组合物
HK40082169B (en) Oral terpene cyclodextrin inclusion complex vehicles
CN101366701A (zh) N，n-二甲基甘氨酸-2，6-二异丙基苯酯盐类注射剂
EP4687857A1 (en) Compositions for treating parkinson's disease and qualitative assessment thereof
CN121197362A (zh) 多肽组合物及其制备方法
BR112018074162B1 (pt) Método para produzir uma composição farmacêutica